|
| 37470150 | Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia. | Haematologica | 2024 |
| 37944143 | How I treat refractory and relapsed acute myeloid leukemia. | Blood | 2024 |
| 36940410 | Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation. | Blood | 2023 |
| 37915564 | CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors. | Front Immunol | 2023 |
| 37756525 | Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy. | Blood | 2023 |
| 37587502 | Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease. | J Hematol Oncol | 2023 |
| 37684299 | Randomized phase-III study of low-dose cytarabine and etoposideâ¿¿+â¿¿/- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia. | Sci Rep | 2023 |
| 37568726 | MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML. | Cancers (Basel) | 2023 |
| 35714312 | Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. | Blood | 2023 |
| 37187198 | Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial. | Lancet Haematol | 2023 |
| 37101762 | Palbociclib in Acute Leukemias With <i>KMT2A</i>-rearrangement: Results of AMLSG 23-14 Trial. | Hemasphere | 2023 |
| 36576532 | Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy. | Ann Hematol | 2023 |
| 34134473 | Fusion genes in acute myeloid leukemia: do acute myeloid leukemia diagnostics need to fuse with RNA-sequencing? | Haematologica | 2022 |
| 35839275 | Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia. | Blood Cancer Discov | 2022 |
| 35729671 | Target capture sequencing reveals a monoclonal outbreak of respiratory syncytial virus B infections among adult hematologic patients. | Antimicrob Resist Infect Control | 2022 |
| 35486475 | Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications. | Blood Adv | 2022 |
| 35875134 | Clonal Evolution at First Sight: A Combined Visualization of Diverse Diagnostic Methods Improves Understanding of Leukemic Progression. | Front Oncol | 2022 |
| 36142824 | Healthy-like CD4<sup>+</sup> Regulatory and CD4<sup>+</sup> Conventional T-Cell Receptor Repertoires Predict Protection from GVHD Following Donor Lymphocyte Infusion. | Int J Mol Sci | 2022 |
| 36204690 | High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative Analysis. | Hemasphere | 2022 |
| 35960871 | Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine. | Blood | 2022 |
| 34995344 | Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. | Blood | 2022 |
| 32241846 | Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia. | Haematologica | 2021 |
| 33598693 | Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. | Blood | 2021 |
| 33903952 | Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q). | Ann Hematol | 2021 |
| 33486841 | Unbalanced translocation der(5;17) resulting in a TP53 loss as recurrent aberration in myelodysplastic syndrome and acute myeloid leukemia with complex karyotype. | Genes Chromosomes Cancer | 2021 |
| 33510405 | Germline variants drive myelodysplastic syndrome in young adults. | Leukemia | 2021 |
| 33564192 | Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. | Nat Med | 2021 |
| 33725366 | Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. | Am J Hematol | 2021 |
| 33556974 | [A supposed hepatocellular adenoma turns out to be intrahepatic splenosis - a case report]. | Z Gastroenterol | 2021 |
| 33929500 | Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. | Blood Adv | 2021 |
| 34889359 | What to use to treat AML: the role of emerging therapies. | Hematology Am Soc Hematol Educ Program | 2021 |
| 34529020 | ALL is not the same in the era of genetics. | Blood | 2021 |
| 34728793 | Correction: Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia. | Leukemia | 2021 |
| 34608129 | Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. | Blood Cancer J | 2021 |
| 34724563 | 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. | Blood | 2021 |
| 34535011 | Clonal expansion of CD8+ T cells reflects graft-versus-leukemia activity and precedes durable remission following DLI. | Blood Adv | 2021 |
| 34350385 | Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial. | Hemasphere | 2021 |
| 34095756 | Treatment for Relapsed/Refractory Acute Myeloid Leukemia. | Hemasphere | 2021 |
| 34172893 | Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. | Leukemia | 2021 |
| 34196171 | A novel classification of hematologic conditions in patients with Fanconi anemia. | Haematologica | 2021 |
| 34047179 | Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with <i>nucleophosmin1</i>-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin. | Haematologica | 2021 |
| 33108522 | Newly diagnosed isolated myeloid sarcoma-paired NGS panel analysis of extramedullary tumor and bone marrow. | Ann Hematol | 2021 |
| 32705308 | Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up. | Ann Hematol | 2021 |
| 32948843 | IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction-a retrospective propensity score analysis. | Leukemia | 2021 |
| 31462736 | Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML). | Leukemia | 2020 |
| 31681986 | FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia. | Br J Haematol | 2020 |
| 31794324 | Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 ÿ 2, Phase II Trial. | J Clin Oncol | 2020 |
| 31851556 | Gemtuzumab Ozogamicin in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. | J Clin Oncol | 2020 |
| 32092477 | Prospective infection surveillance and systematic screening for vancomycin-resistant enterococci in hematologic and oncologic patients - findings of a German tertiary care center. | J Glob Antimicrob Resist | 2020 |
| 33367545 | Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. | Blood | 2020 |